The antidepressant compound, morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, methanesulfonate, or reboxetine, is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has low affinity for other transporters and receptors. The development of reboxetine as a potential antidepressant stems from the prior demonstration that blockade of the NE transporter imparts antidepressant activity. Desipramine, lofepramine, and nortryptiline are examples of tricyclic antidepressant (TCA) compounds from the first generation of antidepressants that exert their effects by blockade of NE reuptake. Maprotiline, a non-tricyclic compound, is also a NE selective reuptake inhibitor. Unfortunately, these antidepressants are also associated with interactions with muscarinic, histaminergic, and adrenergic receptors, which are known to contribute to a variety of untoward side effects. Despite the positive pharmacological profile of reboxetine, i.e., selectivity and specificity, with relatively fewer side effects, its use as an antidepressant is currently limited to Europe. Reboxetine is marketed as Edronax ® in the UK, Norebox ® in Italy, and as Irenor ® in Spain. It is registered in Germany, Sweden, Denmark, Ireland, Austria and Finland. Based on studies conducted primarily outside the US, the FDA granted a preliminary letter of approval in 1999. However, more recent clinical studies conducted in the US and Canada, prompted by the FDA, resulted in a letter of non-approval. To date, it is unclear why the further development of reboxetine as an antidepressant in the US has been halted. Despite this setback, reboxetine has been a valuable pharmacological tool to assess the role of the noradrenergic system in preclinical studies of depressive disorder.
INTRODUCTION
A common theme shared by most antidepressant drugs is an ability to alter levels of the biogenic amine neurotransmitters. Serotonin selective reuptake inhibitors (SSRIs) like fluoxetine, paroxetine and citalopram inhibit the serotonin (5-HT) transporter (SERT) and thereby increase extracellular concentrations of 5-HT. Other classes of antidepressants modulate NE levels via blockade of high affinity, sodium-dependent reuptake into presynaptic terminals through the NE transporter (NET; e.g., desipramine and reboxetine). In recent years, investigators have focused on a number of novel antidepressants that are known to interact with both NE and 5-HT neurotransmission. Mirtazepine, milnacipran, venlafaxine and duloxetine alter both systems through actions on their respective transporters as well as through blockade of specific receptor subtypes (14, 71) . The consensus is that these compounds offer improved efficacy over SSRIs by virtue of their relatively quicker onset of action and their less troubling side effect profile than tricyclic compounds (15, 48, 53, 65, 66, 107) . Reboxetine is selective for the NET but also has an impact on extracellular DA that is presumably taken up by the NET (77, 88) .
Several avenues of research have provided evidence for a role of NE in depression. The initial catecholamine hypothesis of depression was put forward based on the clinical observation that drugs that reduced NE (and other amines) in the brain resulted in a lowering of mood (36) . In contrast, drugs that increased these levels seemed to alleviate symptoms of depression (22, 42) . This hypothesis has been revised since the discovery that serotonin also appears to play a crucial role in the actions of antidepressants. Changes in protein levels or in gene expression of several enzymes important for monoamine synthesis, degradation and inactivation have been associated with depression. For example, expression of tyrosine hydroxylase (TH), the rate limiting enzyme for NE biosynthesis has been reported to be greater in the locus coeruleus (LC) of depressed suicide victims (72) . A deficiency of NE in depression is indicated by post-mortem data provided by Klimek and coworkers. In their study a reduction of NET in the midcaudal portion of the LC from suicide victims was reported. They suggest this decrease may reflect a compensatory downregulation of the transporter protein in response to insufficient levels of its substrate (NE) at the synapse (51) . In preclinical studies, chronic treatment with antidepressants has been shown to alter expression of TH (19, 60, 70, 87) . Conflicting reports of genetic linkage and association between monoamine oxidase A (MAO-A), monoamine oxidase-B (MAO-B) and manic-depressive illness exist. Activity of catechol-O-methyltransferase (COMT) has been shown to be lower in patients with bipolar and major depressive disorder in one study (47) but this was refuted by several others (3, 38, 41) . Contradictory reports of changes in adrenergic receptors in depression have also been published. Zanko and Beigon (111) and Mann et al. (56) reported increased density of â-adrenergic receptors in suicides, whereas De Paermentier et al. (28) reported no change. Despite the lack of consensus, the timecourse for therapeutic efficacy closely follows that reported for the downregulation of â-receptors (97, 106) . Furthermore, evidence from a wide range of preclinical and clinical studies supports the hypothesis that monoamine neurotransmission is involved in the pathology and/or the treatment of affective disorders (4, 21, 34, 55, 86, 90) .
Although combination therapy has been shown to be more effective in subpopulations of depressed patients, some individuals respond better to SSRIs and still others respond more robustly to treatment with selective noradrenergic reuptake inhibitors (SNRIs) (71, 89, 94, 103) . Thus alterations in both 5-HT and NE systems appear to contribute to depressive disorders but not necessarily in a predictable way. This further underscores the complex etiology of depressive disorders. Nonetheless, valuable information has been gained from preclinical studies that examine the specific neurochemical effects of treatment with the range of antidepressant compounds currently used in treatment. There are a number of potential sites where NE and 5-HT may interact. For example, both systems send widespread projections throughout the brain. Inhibitory autoreceptors are indirectly stimulated by reuptake inhibitors, as are postsynaptic receptors. The monoamine receptors are linked via G-proteins to second messenger systems that regulate gene expression. Synergistic effects may be achieved through stimulation of convergent pathways. Reboxetine, the first selective norepinephrine reuptake inhibitor promises to provide relief to those that suffer from depression. Its low affinity for CNS receptors limits the number of complicating side effects and increases patient compliance.
PRECLINICAL STUDIES

In Vitro Assays
The selectivity of reboxetine was determined by assays using MDCK (Madin-Darby canine kidney) cell lines expressing either human serotonin transporters or human norepinephrine transporters. IC 50 values were determined by nonlinear curve fitting of the data from individual experiments. Reboxetine was shown to dose-dependently block [ 3 H]dopamine uptake into hNET cells with a potency of 11 nmol/L. In a test of 39 receptors, channels and enzyme assays reboxetine showed poor affinity at all CNS receptors ( Table 2 ). The histamine H 1 and serotonin 5-HT 2C receptors showed higher affinity but still more than 1000-fold less than its affinity for the NET (109) .
In a study designed to determine whether reboxetine had any potential therapeutic value as an adjunct for smoking cessation, Miller and coworkers found that at concentrations that did not exhibit intrinsic activity, reboxetine potently inhibited (IC 50 value = 7.29 nM) nicotine-evoked [ 3 H]NE overflow from superfused hippocampal slices via a noncompetitive mechanism (63) . This action was independent of the NET as demonstrated with desipramine in the superfusion buffer and thus suggests some inhibitory activity at nicotinic ACh receptors. More sophisticated studies examined which receptor subtypes were affected by reboxetine and it was found that reboxetine interacts with the á 3 â 4 subtype with the highest affinity. Rauhut and colleagues recently reported the ability of reboxetine to attenuate nicotine self-administration by rats (~60% reduction). The inhibition of nicotine self-administration achieved by reboxetine was comparable to that observed with mecamylamine, a classical noncompetitive antagonist at nicotinic receptors. The doses tested only moderately affected sucrose, maintained responding (~20% reduction) and did not alter baseline locomotor activity (85) . These findings are interesting with regards to the potential link between depression and smoking. The incidence of major depression is higher in smokers than non-smokers (20, 35, 49) and the ability to quit smoking is greater in non-depressed individuals (24, 35) . One hypothesis is that those experiencing symptoms of depression attempt to self-medicate with cigarettes (57) . The findings with reboxetine are consistent with those reported for bupropion's actions as a smoking cessation agent. Bupropion also acts as a weak inhibitor of both DA and NE transporters (32, 33, 61) and an antagonist at nAChRs (62, 93) . Chronic reboxetine treatment alters cAMP-dependent kinase and CaMKII. A reduction in cAMP binding to the regulatory subunit of PKA in the microtubule and cytosol fractions was observed (67) . Long-term reboxetine treatment was also associated with CaMKII mediated phosphorylation of a presynaptic fraction in the hippocampus rich in synaptic vesicles. This finding is consistent with the actions of other types of antidepressants administered long-term (80, 81) . (44, 77, 88) . All reports show that systemic administration of reboxetine results in an increase in extracellular NE and a smaller increase in extracellular DA with little or no effect on extracellular 5-HT. Some discrepancy exists with regard to the effect of long-term administration of reboxetine (see below). Reserpine induced blepharospasm and clonidine induced hypothermia could be reversed by reboxetine (109) .
In Vivo Assays
Depression models
In the tail suspension test, reboxetine, 30 mg/kg i.p., reduced immobility time in mice (25, 109) . Behavioral studies in rats also demonstrated anti-immobility effects of reboxetine (25, 26, 40, 75) . Reboxetine was also shown to be active in the olfactory bulbectomy (OB) rat model of depression (39) . No disruptive effects on cognition or psychomotor performance have been noted. The majority of basic research done in the depression field is either focused on describing (82, 83) and has since been widely used as a screening test to detect antidepressant activity in both rats and mice (84) . When rodents are placed in an inescapable chamber of water they typically struggle initially but eventually become relatively immobile. The rat FST requires an initial exposure on Day 1 that facilitates the development of immobility during test in Day 2. Administration of antidepressants over the intervening 24 h (3 injections) results in a reduction of immobility. Several recent studies have further characterized the specific effects of antidepressants of distinct classes. For example, administration of serotonin selective reuptake inhibitors (SSRIs) reduces immobility and increases the duration of swimming behavior, whereas noradrenergic enhancing compounds increase climbing behavior along with reductions in immobility (30, 76) . A number of studies have been recently published describing the ability of reboxetine to reduce immobility in the forced swimming test. Wong and colleagues reported significant decreases in immobility detected at doses as low as 4 mg/kg. In a study by Connor et al., reboxetine was shown to reduce immobility and defecation in the FST in a dose-dependent manner. The attenuation of defecation is thought to reflect a reduction in the emotional reactivity. Additionally, reboxetine produced a modest but non-significant decrease in serum corticosterone elicited by swim exposure (23) . Reboxetine treatment reduced FST-induced increases in 5-HT turnover in the amygdala and frontal cortex and DA turnover in the striatum. From these data it is concluded that reboxetine acts not only on noradrenergic systems but also alters the stress-elicited responsiveness of 5-HT, DA and hypothalamic systems. The mouse FST is similar to the rat FST but only requires a single injection of antidepressant 30 min prior to a single swim exposure. The activity of the mice is recorded on videotape for six minutes and the duration of immobility is assessed during the last 4 min of the test. Reboxetine (10 mg/kg) was shown to have an antidepressant-like effect in the mouse FST (25, 109) . Mice that have targeted disruption of the dopamine-â-hydroxylase gene (Dâh -/-), the enzyme responsible for the synthesis of NE and epinephrine were evaluated in the FST to specifically test the role of NE in mediating behavioral changes elicited by antidepressants. There was no difference in baseline immobility scores in the forced swim test between Dâh +/-mice, which have normal levels of NE, and Dâh -/-mice. However, the Dâh -/-mice failed to demonstrate antidepressant-like behavioral effects following the administration of several classes of antidepressants. These included the NE reuptake inhibitors desipramine and reboxetine, the monoamine oxidase inhibitor pargyline, and the atypical antidepressant bupropion. In addition, desipramine significantly reduced immobility in the Dâh -/-mice following pretreatment with the synthetic NE precursor L-threo-3,4-dihydroxyphenylserine (DOPS), but not saline. Biochemical studies showed that there was no significant difference in the regional brain levels of NE transporter immunoreactivity or monoamine oxidase activity, the primary targets for most of the compounds examined (25) .
Reboxetine has been shown to inhibit LC neuronal discharge rates in a dose dependent manner (ED 50 = 191 ± 37 ìg/kg, i.v.). This could be reversed by administration of the á 2 antagonist, idazoxan (99) . In this study, no effect on 5-HT discharge was observed. Reboxetine was found to have a nearly 30-fold greater in vivo selectivity for inhibiting LC neurons compared to DR neurons. No significant effect on firing activity of DA neurons was observed at doses up to 10 mg/kg.
In a recent study we combined in vivo microdialysis with the FST and demonstrated the antidepressant-like activity of reboxetine is correlated with changes in extracellular NE in the frontal cortex of rats (Figs. 1 and 2) (75). In particular, increases in climbing activity were positively correlated with change in NE output during the FST (Fig. 2) . The amount of NE elicited by the FST was negatively correlated with measures of immobility while . Rbx #1 (second up arrow) is the first reboxetine injection given after exposure to swimming on day 1. The second reboxetine injection occurred 5 h prior to the test swim and is not shown in the figure. Rbx #3 is the final reboxetine injection given on day 2, 1 h prior to the swim. The behavioral and neurochemical data in A and B were collected from the same group of animals (n = 7). Differences in behavioral scores between days 1 and 2 were determined using Student's paired t-test (*P < 0.05; **P < 0.01). Reproduced with permission from ref. 75. having no impact on swimming behavior. This provides further evidence for the important role of norepinephrine in the actions of antidepressants.
Stress is well known to activate the monoamine systems and is often associated with the precipitation of depressive disorders (5, 6, 58, 59) . The ability of reboxetine to alter the response to stressors is an important factor to consider when assessing its role as an antidepressant. A wealth of data supports the notion that the inability to cope with stress is a major risk factor for depression (5) . The noradrenergic system is critically linked to stress and is, therefore, a likely substrate to target for therapeutic intervention. The noradrenergic system, especially that arising from the LC, is activated by a wide variety of stressors, including environmental stimuli as well as internal cues such as hypotension, hypoglycemia and distention of visceral organs (1,2,10,11,68,69,74,78) . The neurons of the LC are sensitive to changes in the internal and external environment, especially when these cues are salient for the organism's survival.
Studies utilizing in vivo microdialysis have shown that presentation of an acute stressor typically results in a brief increase in extracellular NE with a return to basal levels shortly after termination of the stressor (73, 77) . This is consistent with electrophysiological data recorded from LC neurons during presentation of stressors or challenges (74, 78) . It is thought that a responsive noradrenergic system is an important component of an adaptive response to stress. However, if the system is pushed too hard or required to respond at high levels for an extended period of time, this response appears to become maladaptive. We recently reported the ability of chronic reboxetine administration to alter the noradrenergic response to stress. Animals were implanted with in vivo microdialysis probes in the frontal cortex. On the day of the experiment baseline values were monitored for 2 h prior to administration of reboxetine. A tailpinch stress was applied 100 min after drug injection. Stress exposure consisted of application of an artery clamp approximately 5 cm from the tip of the rat's tail for 20 min. The NE response in rats that received an acute injection of saline (vehicle) prior to tailpinch was an increase of 54%, similar to the increase (44%) seen in rats treated with an acute injection of reboxetine, 10 mg/kg i.p. In contrast, rats that received a higher dose of reboxetine, 20 mg/kg, showed a much greater response (95% increase) that was prolonged for up to 2 h post-stress (see Fig. 3 ). In chronically treated rats, osmotic minipumps containing reboxetine, 10 mg/kg/day, were implanted 14 days prior to the test day. Chronic reboxetine treatment appeared to normalize the NE response to tailpinch stress. Despite a 4-fold increase in extracellular NE achieved by constant reboxetine administration through the minipump, an increase of 33% was demonstrated and this response was of a shorter duration, similar to that observed in chronic vehicle control rats (41% increase; Fig. 4 ). Local administration of clonidine through the dialysis probe resulted in a significantly smaller decrease in NE in the group treated chronically with reboxetine compared to chronic saline. This suggests a possible desensitization of á 2 -adrenergic autoreceptors. However, because only limited studies were done and the much greater basal levels of NE achieved during chronic reboxetine administration, it is not possible to make this conclusion. Reboxetine, 20 mg/kg i.p., increased extracellular DA by 2-fold when administered acutely or chronically. Furthermore, reboxetine appeared to enable the DA system to respond to tailpinch stress. Saline injected controls did not show a response to tailpinch but both acute and chronic reboxetine resulted in a significant increase in DA following tailpinch (77) . No effect on extracellular 5-HT was observed. Sacchetti and colleagues found somewhat different effects of chronic reboxetine treatment on extracellular NE levels (88). They reported a 242% increase in NE in the frontal cortex and a similar increase (240%) in the hippocampus following acute reboxetine administration (15 mg/kg i.p.). They found no difference between chronic reboxetine and chronic saline treated animals when challenged with an acute reboxetine injection 24 h after the last injection. They also examined the effect of á 2 antagonists on extracellular NE when combined with reboxetine. The increase was potentiated but they found no evidence for adaptation of the noradrenergic system in these studies. Under these experimental conditions that differ from the Page studies, it is possible that the route of administration of reboxetine and the time at which they examined the response to acute reboxetine challenge contribute to these differences. In fact, in a more recent study, they administered reboxetine through osmotic minipumps and found similar effects, i.e., smaller reductions of NE following local administration of clonidine (44) . The DRL 72 test is a lever pressing task that is used to measure the response efficiency of rats. This test is sensitive to the effects of antidepressant drugs and is used to predict clinical efficacy of novel compounds (12) . This test reinforces responses that are separated by at least 72 sec. Water deprived rats must wait at least this long between lever presses to receive water reward. If the lever is pressed before this interval, the 72 sec waiting period is reset. The administration of antidepressants results in a change in the temporal response pattern i.e., response rate decreases or remains the same while the reinforcement rate increases. The ability of antidepressants to alter the response profile has been described as an increase in the rat's ability to wait. This could be perceived as better impulse control. Reboxetine was shown to increase the efficiency of responding and reduce the number of responses emitted. The effects of reboxetine at all doses tested were comparable to those of desipramine at 10 and 20 mg/kg (29) .
The reciprocal connections between noradrenergic locus coeruleus (LC) neurons and serotonergic neurons and their mutual responsiveness to stress suggests that disruption of the interaction between these systems is a potential substrate involved in the pathophysiology of depressive disorders. Most effective antidepressant compounds directly interact with these neurotransmitter systems. It is known that the noradrenergic influence on dorsal raphe (DR) firing rate is excitatory (13) and that 5-HT attenuates glutamate-or sensoryevoked responses of LC neurons (9) . Serotonergic innervation of the LC originates from 5-HT containing cell bodies in the DR, the median raphe (MR) and other pontine 5-HT neurons including pericoerulear cells (52, 54) . Electrical or chemical stimulation of the DR elicits release of 5-HT in the LC region (46) . Furthermore, infusion of 8-OH-DPAT, a 5-HT 1A agonist, in the DR lowers levels of 5-HT in the LC (46) . Firing rate of DR neurons (95, 96) , 5-HT release (92) and 5-HT synthesis (43) are negatively influenced by activation of 5-HT 1A receptors located on cell bodies and dendrites of DR neurons.
Early studies by Aghajanian and colleagues demonstrated that the noradrenergic projections to the raphe nuclei exerted an excitatory influence on 5-HT neurons through postsynaptic á 1 -receptors (13) . Important interactions between these two systems can also occur in terminal regions (102) . For example, 5-HT 2A/C receptors are located on dendrites of pyramidal cells in the frontal cortex (45, 79) . Dopaminergic and adrenergic receptors are also found prominently on these neurons and therefore represent yet another site where potential interactions may occur (7, 8) . A detailed series of studies by Blier and colleagues has further characterized the 5-HT receptor subtype distribution in the LC region that is responsible for regulation of LC firing by 5-HT (100). These data support a mechanistic link between norepinephrine and serotonin whereby a disruption of the appropriate balance of these monoamines may result in disorder of affective state. As mentioned above, reboxetine had no direct effect on extracellular 5-HT. It is possible however, that through reboxetine's actions on the noradrenergic and dopaminergic systems, 5-HT neuronal activity could be modified. Interestingly, the class of antidepressant (i.e., SSRI or SNRI), while selective, may impact on other systems by restoring important interactions.
CLINICAL STUDIES
Recently, Schwartz et al. presented findings from a double blind comparison of reboxetine with venlafaxine in a group of patients with a HAM-D-17 item total score ³25 (91). In week 8 of treatment a marked reduction (50% or greater) of total scores in both reboxetine and venlafaxine treated subjects was reported in 56% and 54% of the patients, respectively. Overall 24% of the patients were classified as being in remission after 8 weeks of treatment but the rate of remission was greater in the reboxetine treated group. In another double-blind, randomized multicenter trial conducted by Berzewski, further support for the effectiveness of reboxetine (16) was provided. After six weeks of treatment 69% of patients treated with reboxetine and 56% treated with imipramine were considered responders and 52% of reboxetine treated patients and 45% of the imipramine patients were considered in remission. Data from four double blind studies of severely depressed (defined by a Hamilton Rating Scale for Depression (HAM-D) score ³25) individuals that received chronic reboxetine, 8-10 mg/day, demonstrated a significantly greater reduction of HAM-D score than placebo-treated patients. The overall mean responder rate (defined as change in HAM-D >50% between baseline and last follow-up) was 63% in reboxetine treated patients compared to only 36% in placebo treated patients (64) .
An open-label study of reboxetine (at a dosage range of 2-16 mg/day) in a population of mostly treatment-resistant patients culled from six clinical academic settings in Canada reported that 56% of patients were either very much or much improved, 18% were minimally improved, while 16% experienced no change and 11% were much worse (50) . Reboxetine has also been shown to reduce anxiety. In a six-week open label trial 24 of 29 outpatients with panic disorder that failed to respond to SSRIs were found to be responsive to reboxetine. A significant reduction in the number of panic attacks and improved scores on scales measuring anxiety and depression was observed (27) .
Depression is a complicated disorder with a range of symptoms that are not easily categorized. One obstacle that is crucial in the recovery process is the ability of an individual to appropriately interact with their environment, including fulfillment of work obligations, social activities and relationships with close friends and family members. Often improvement of many of the symptoms of depression occurs following pharmacotherapy but impairment of social functioning persists and goes undetected by more traditional assessment scales. The use of self-assessment accounts for the importance of the patient's perspective is a valuable index. The Social Adaptation Self-evaluation Scale (SASS) is a 21-item scale used to evaluate social motivation and behavior in patients diagnosed with depression. This scale has been validated as reliable and sensitive to change as well as easy to administer. The SASS has been useful as a tool to more carefully dissect the particular subtle variations in aspects of human behavior that are affected in depression and may provide a more sensitive measure for improvement during antidepressant therapy (17, 18) . The SASS is thought to measure nuances of treatment efficacy that can be missed by traditional observer-based rating scales. The SASS may reflect overall perception of the impact of treatment. This is typically a mixture of the perceived improvement and the impact of side effects on the patient's ability to function in a social context.
Using the SASS as an index, reboxetine was found to be more efficacious for improvement of social function. The SASS improved by 10.3 points in the reboxetine recipients compared with only 7.6 points in fluoxetine treated patients. In long term treatment with reboxetine, a subset of patients that achieved remission were shown to have even greater increases in SASS (16.2) compared to fluoxetine recipients (9.7). Reboxetine was also demonstrated to be more efficacious in severely depressed patients compared to fluoxetine (105) . Reboxetine was found to improve patient motivation and self-perception. Reboxetine has also been shown in an open label study to be effective at alleviating depression-related anxiety in patients with panic disorder that did not respond to SSRI therapy (27) .
The search for better antidepressant compounds is in part due to the associated side effects with many of the existing treatments. For example, although desipramine is quite effective, it is associated with many unpleasant side effects that limit patient compliance. Monoamine oxidase inhibitors are non-selective and irreversible. Dry mouth, constipation, cardiac arrhythmia, orthostatic hypotension and sedation are among the side effects elicited by antidepressants. Because SSRIs were shown to elicit far fewer side effects than TCAs, a large increase in the number of prescriptions for this class was observed although no significant increase in efficacy was detected. However, some common side effects of the SSRIs do occur and these include early nausea and chronic sexual dysfunction; thus the search for better drugs continues.
Data from over 1,000 patients that received reboxetine has been compared with patients that received either other drugs or placebo. Reboxetine was found to have no significant cardiovascular effects, a low potential for drug interactions, no cognitive or motor function impairment and no increase in suicidal ideation. Furthermore, no evidence of drug withdrawal has been reported for reboxetine after either abrupt or tapered discontinuation (101) . A small percentage of patients reported sexual dysfunction and only at doses higher than 8 mg/day. The general tolerability and safety of reboxetine is thus superior to many other currently prescribed antidepressants.
Most of a single dose of reboxetine is excreted after 96 h. A small percent (10-15%) is excreted in the feces. Less than 10% of the dose is cleared renally. The primary route of reboxetine elimination appears to be through hepatic metabolism (31) . Plasma proteins bind most of the drug and thus the ability to interact with other receptors is very unlikely at clinically relevant doses. The t 1/2 for reboxetine in humans is 13 h, which allows for twice daily dosing. As mentioned above, SSRIs are plagued by sexual dysfunctions and gastroenterological disorders as well as inhibition of the hepatic cytochrome P450 enzymes (104) . Reboxetine is metabolized by cytochrome P450 3A4 (CYP450 3A4) (108) . No effects on the major isoenzymes involved in drug metabolism have been reported and thus no major drug-drug interactions are known to occur. Reboxetine has only supramicromolar affinity for H 1 histaminergic, muscarinic and á 1 -adrenergic receptors whereas all the other TCAs have nanomolar affinity. The major side effects associated with reboxetine treatment are constipation and dry mouth. Both desipramine and reboxetine are associated with reports of dry mouth. The salivary glands receive both sympathetic and parasympathetic innervation. The excitatory influence on salivary output is mediated by á 1 -receptors on preganglionic sympathetic neurons but this is opposed by inhibition me-diated through á 2 receptors on preganglionic parasympathetic neurons (98) . The higher report of dry mouth as an adverse effect in patients treated with desipramine is likely due to direct blockade of muscarinic receptors on salivary glands. Less frequently encountered side effects include CNS disorders, hypotension, nausea, hyperhidrosis, chills, tachycardia, dizziness, drowsiness, fatigue, headache and insomnia. In rare instances, reboxetine has been associated with arrhythmias. One case has been reported with hyponatremia and inappropriate antidiuretic hormone secretion with reboxetine treatment. There are no reports of adverse interactions with alcohol. Reboxetine has not been associated with the induction of mania.
DISCUSSION
The prevalence rate of depression has been reported to be as high as 17% (110) . This is a remarkably large number and has significant impact with an estimated annual cost in the US at approximately $44 billion in 1990 (37) . Certainly this number has escalated in the past decade. The economic costs of depression are due not only to the price of healthcare but also more importantly to the loss of productivity in the workforce and burden to families with depressed individuals. Clearly, the search for more effective therapeutic strategies has wide benefit and should continue to be a priority of the research community. The wide range of depressive disorders and the lack of a highly successful and consistent treatment strategy underscores the likely diverse nature of the pathology. The apparent improvement in social functioning with reboxetine compared to SSRIs supports the idea that pharmacologically distinct pathways mediate subtle aspects of depressive symptoms. In particular, a distinction between serotonin and mood regulation vs. the role of norepinephrine in sustaining drive is supported by the recent clinical data reviewed above. Because some individuals respond better to SSRIs while others are more responsive to NRIs and still a subpopulation receives therapeutic relief from mixed compounds, it is essential to continue efforts to delineate the mechanisms of action of these compounds and attempt to identify convergent brain systems that are affected in the spectrum of affective disorders.
